Factors influencing the choice of monoclonal antibodies for antibody–drug conjugates

Research output: Contribution to journalReview articlepeer-review

12 Citations (Scopus)

Abstract

In antibody–drug conjugates (ADCs), monoclonal antibodies (mAbs) act as carriers for a cytotoxic payload providing the therapy with targeted action against cells expressing a target cell surface antigen. An appropriate choice of mAb is crucial to developing a successful ADC for clinical development. However, problems such as immunogenicity, poor pharmacokinetic (PK) and pharmacodynamic(PD) profiles and variable drug–antibody ratios (DARs) plague ADCs. In this review, we detail recent mAb-based innovations and factors that should be considered to overcome these problems to achieve a new generation of more effective ADC therapeutics.
Original languageEnglish
Pages (from-to)354-361
Number of pages8
JournalDRUG DISCOVERY TODAY
Volume27
Issue number1
DOIs
Publication statusPublished - Jan 2022

Fingerprint

Dive into the research topics of 'Factors influencing the choice of monoclonal antibodies for antibody–drug conjugates'. Together they form a unique fingerprint.

Cite this